Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 14/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556304 | 0.83 | RXFP1 (0.42) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL23713153 | 0.81 | RXFP1 (0.49) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL22571388 | 0.78 | RXFP1 (0.39) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL22556325 | 0.73 | RXFP1 (0.50) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL22556312 | 0.73 | RXFP1 (0.50) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL23713155 | 0.72 | RXFP1 (0.41) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL22556341 | 0.72 | RXFP1 (0.51) | RXFP1MAPK8TAS2R14ABCG2AKR1C3 | |
| SCHEMBL23713160 | 0.71 | RXFP1 (0.47) | RXFP1MAPK8TAS2R14ABCG2POLB | |
| SCHEMBL23112794 | 0.70 | RXFP1 (0.52) | RXFP1MAPK8TAS2R14ABCG2AKR1C3 | |
| SCHEMBL23713115 | 0.70 | RXFP1 (0.42) | RXFP1MAPK8TAS2R14ABCG2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885MAPK8 986/4885TAS2R14 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.